Replidyne to Report 2007 Fourth Quarter and Year-End Earnings
05 Febbraio 2008 - 1:30PM
PR Newswire (US)
Presenting at BIO CEO & Investor Conference LOUISVILLE, Colo.,
Feb. 5 /PRNewswire-FirstCall/ -- Replidyne, Inc. (NASDAQ:RDYN)
announced today that it will host a conference call on Tuesday,
February 26, 2008 at 4:45 P.M. ET to report 2007 fourth quarter and
year-end earnings. Additionally, Replidyne will present at an
upcoming investor conference in February 2008. Earnings conference
call information is as follows: Kenneth J. Collins, President and
CEO, and other members of Replidyne's senior management team will
provide a company update and discuss earnings results via
conference call and webcast on Tuesday, February 26, 2008, at 4:45
P.M. ET. Callers may participate in the conference call by dialing
866-510-0707 (domestic) or 617-597-5376 (international), and
providing the passcode 33794809. To access the live webcast, please
log on to the company's website at http://www.replidyne.com/ and go
to the Investor Relations section. A replay of the conference call
will be available approximately one hour after completion of the
call through Tuesday, March 11, 2008 at midnight. Callers may
access the replay by dialing 888-286-8010 (U.S. participants) or
617-801-6888 (international participants). The audio replay
passcode is 92464480. To access a replay of the webcast, visit the
Investor Relations section of the company's website at
http://www.replidyne.com/. Investor conference presentation
information is as follows: -- Mr. Collins will present on Tuesday,
February 12, 2008 at 2:45 P.M. ET at the BIO CEO & Investor
Conference, to be held at the Waldorf-Astoria in New York City. A
live audio webcast of this presentation will be available on the
investor relations section of the company's website at
http://www.replidyne.com/. The webcast will be archived and
available on Replidyne's website after the event for a period of 30
days. -- At the same conference, Replidyne's Chief Commercial
Officer Peter Letendre, Pharm.D. will participate on antibiotics
panel "Super Drugs Against Super Bugs" on Wednesday, February 13,
2008 at 9:30 A.M. About Replidyne, Inc. Replidyne is a
biopharmaceutical company focused on discovering, developing,
in-licensing and commercializing innovative anti-infective
products. Replidyne's lead product, faropenem medoxomil, is a novel
oral community antibiotic, expected to be appropriate for use as a
first-line antibiotic for treatment of respiratory and skin
infections in adult and pediatric patients. Replidyne's
investigational antibacterial agent REP3123 targets Gram-positive
C. difficile bacteria and C. difficile-associated disease (CDAD).
Replidyne is pursuing the development of other novel anti-infective
programs based on its DNA replication inhibition technology and its
in-house discovery research. Safe Harbor This press release
contains plans, intentions, objectives, estimates and expectations
that constitute forward-looking statements about Replidyne, Inc.
that involve significant risks and uncertainties. Actual results
could differ materially from those discussed due to a number of
factors including, the success and timing of pre-clinical studies
and clinical trials; the Company's ability to obtain a new partner
for faropenem on acceptable terms; the Company's ability to obtain
and maintain regulatory approval of product candidates and the
labeling under any approval that may be obtained; plans to develop
and commercialize product candidates; the loss of key scientific or
management personnel; the size and growth of the potential markets
for the Company's product candidates and the Company's ability to
serve those markets; regulatory developments in the U.S. and
foreign countries; the rate and degree of market acceptance of any
future products; the accuracy of Company estimates regarding
expenses, future revenues and capital requirements; the Company's
ability to obtain and maintain intellectual property protection for
our product candidates; the successful development of the Company's
sales and marketing capabilities; the success of competing drugs
that are or become available; and the performance of third party
manufacturers. These and additional risks and uncertainties are
described more fully in the Company's most recent Form 10-Q filed
with the SEC under the Securities Exchange Act of 1934. Copies of
filings made with the SEC are available through the SEC's
electronic data gather analysis and retrieval system (EDGAR) at
http://www.sec.gov/. All forward-looking statements made in the
press release are made as of the date hereof and the Company
assumes no obligation to update the forward-looking statements in
the document. DATASOURCE: Replidyne, Inc. CONTACT: Sabrina B. Oei,
Dir. Investor & Public Relations of Replidyne, Inc.,
+1-303-996-5535 Web site: http://www.replidyne.com/
Copyright
Grafico Azioni Replidyne (MM) (NASDAQ:RDYN)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Replidyne (MM) (NASDAQ:RDYN)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Replidyne (MM) (NASDAQ): 0 articoli recenti
Più Replidyne (MM) Articoli Notizie